Key result
Serum betatrophin levels did not significantly differ between obese children with or without non-alcoholic fatty liver disease and healthy non-obese controls.
Why the study?
Are serum betatrophin levels associated with non-alcoholic fatty liver disease and metabolic parameters in obese children?
Observational (n=82)
No
Are serum betatrophin levels associated with non-alcoholic fatty liver disease and metabolic parameters in obese children?
Serum betatrophin levels do not appear to be elevated or correlated with metabolic parameters in obese children with non-alcoholic fatty liver disease.
Betatrophin may associate with pediatric NAFLD in obesity; leaves open biomarker or therapeutic role pending prospective validation.
PURPOSE: The prevalence of obesity has significantly increased among children and adolescents worldwide and is becoming an important health care problem in parallel with the increased prevalence of obesity pediatric non-alcoholic fatty liver disease. Betatrophin is a newly define hormone that is commonly secreted by liver and plays role in glucose tolerance. This study aimed to investigate the relationship between serum betatrophin levels and non-alcoholic fatty liver disease in obese children. METHODS: The study included 40 obese children with a body mass index (BMI) above 95th centile, and 35 non-obese subjects with a BMI 3-85th centile, whose age and gender were similar to those of the patient group. For the evaluation of metabolic parameters fasting serum glucose, insulin, alanine aminotransferase, aspartate aminotransferase, lipid profile and serum betatrophin levels were measured. Total cholesterol: high-density lipoprotein cholesterol and low-density lipoprotein cholesterol: high-density lipoprotein cholesterol ratios were calculated as "atherogenic indices." Betatrophin levels were not correlated with the metabolic parameters. CONCLUSION: In the present study, levels of betatrophin are not different between obese and insulin resistant children and non-obese subjects, and they are not correlated with atherogenic indices. To elucidate the exact role of betatrophin in obesity, further studies are required to identify the betatrophin receptor and/or other possible cofactors.
No takes yet. Share an insight, caveat, or question.
Battal et al. (2018) conducted an observational in Obesity and Non-Alcoholic Fatty Liver Disease (NAFLD) (n=82). Obesity and NAFLD vs. Healthy non-obese controls was evaluated on Serum betatrophin levels (p=0.90). Serum betatrophin levels did not significantly differ between obese children with or without non-alcoholic fatty liver disease and healthy non-obese controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: